The group's principal activities are to develop gene therapy and cell therapy products and technologies for the treatment of acquired and inherited diseases. the gene therapy products are designed to treat diseases by regulating cellular function at a genetic level. the cell therapy involves transplanting living cells into a patient to treat diseases, either in place of, or in combination with, other pharmaceuticals. currently, the group has ongoing preclinical product development activities in the areas of cystic fibrosis, hemophilia a, arthritis, cancer, lysosomal storage disorders, cardiovascular diseases and aids prophylaxis. the product candidates under clinical development program includes tgaavc-f for treatment of cystic fibrosis and tgddc-e1a for treatment of cancer. in addition to gene therapy, the group has also patents in cell therapy used for treatment of infectious diseases and cancer.